Identification of central nervous system involvement for patients with AIDS-related lymphomas

May 30, 2014, Fox Chase Cancer Center

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.

In a new study led by Fox Chase Cancer Center Hematologist and Oncologist Stefan K. Barta, MD, MS, MRCP, researchers report that CNSi – identified at the time of an ARL diagnosis – does not appear to have an impact on overall survival. Dr. Barta's collaborators will present the findings at the 50th Annual Meeting of the American Society of Clinical Oncology.

In the same study, he and his team found that patients with CNSi at the time of diagnosis were nearly three times as likely, on average, to have CNS relapse (CNSr) during cancer treatment. CNSr is generally associated with particularly poor prognosis.

"It occurs early and usually has a poor outcome, though there are long term survivors," said Dr. Barta. He hopes a better understanding of how CNS involvement affects prognosis could lead to improvements in diagnostic tools and treatments.

Infection with human immunodeficiency virus, or HIV, greatly increases a person's risk of being diagnosed with many lymphomas. AIDS-related lymphomas (ARL), which include diffuse large cell lymphomas and small noncleaved cell lymphomas, are particularly aggressive forms of disease. The vast majority of patients—at least 80 percent, according to the National Cancer Institute—have stage IV disease at the time of presentation. The is among the most common sites outside the lymph nodes that may be involved with ARL.

In 2013, as part of a study on factors that influence outcomes for patients with ARL, Dr. Barta led the assembly of a database containing medical data from more than 1500 patients newly diagnosed with AIDS-related lymphomas who participated in clinical trials in Europe and the United States between 1990 and 2010, inclusive.

In the new study, he and his colleagues used the same database to identify 880 patients with ARL whose data included complete information on central involvement (CNSi) at diagnosis and relapse (CNSr).

They analyzed data to identify associations between CNSr and a variety of patient characteristics, including age, sex, CD4 count, treatment history with cART, lymphoma subtype, rituximab use, and type of initial chemotherapy. Only CNSi conferred a higher risk of relapse.

CNSi was identified in 13 percent of all 880 patients at the time of diagnosis, including 27 percent of patients with Burkitt Lymphoma or Burkitt-like lymphoma and 6 percent in patients with diffuse large B-cell lymphoma. Dr. Barta and his colleagues found that 5.3 percent of patients experienced CNSr a median of 4.2 months after diagnosis; those patients had a median overall survival of 1.6 months.

Sixty-nine percent—607 patients—had been treated with combination anti-retroviral therapies, or cART. These therapies, which came into use in 1996, reversed the dismal survival rates for patients with full-blown AIDS and slowed the onset of AIDS for patients infected with HIV. However, Dr. Barta and his team found that cART did not reduce the frequency of CNSr in patients diagnosed with ARL. Neither did other treatments the patients had received, which included combination chemotherapies with or without rituximab—a monoclonal antibody that acts against B-cells.

"Over the last few years, people have realized that intrathecal CNS prophylaxis is probably inadequate, at least for diffuse large B-cell lymphomas, and many physicians have abandoned it," said Dr. Barta.

Dr. Barta, whose research focuses on ARL, said his findings suggest the approaches used to identify CNS involvement may be missing many patients who are at risk of CNS relapse, and current treatments are insufficient.

"A lot of patients who relapsed probably had undetected CNS involvement at diagnosis," he said. "We want to figure out if there are better strategies to identify at risk."

Explore further: HIV-associated lymphoma survival has not improved during the antiretroviral therapy era

Related Stories

HIV-associated lymphoma survival has not improved during the antiretroviral therapy era

July 27, 2013
Stable survival rates were observed for HIV-associated lymphoma patients during the antiretroviral therapy (ART) era in the US, according to a new study published July 26 in the Journal of the National Cancer Institute.

Big data to help blood cancer patients

May 20, 2014
A pioneering database at the University of Leeds will help match patients with certain types of blood cancers to the best treatments.

Genome sequencing of Burkitt Lymphoma reveals unique mutation

November 12, 2012
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and ...

Body kills 'spontaneous' blood cancers on a daily basis, research finds

February 2, 2014
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found.

PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients

August 1, 2013
A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma (DLBCL)—a key factor in tailoring patient management plans—has been identified by researchers in a study published ...

New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test

May 23, 2014
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated ...

Recommended for you

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.